CCXI Trading Analysis - 10/22/2026 03:33 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for CCXI (ChemoCentryx / now part of Gilead-focused pipeline history):

• CCXI previously faced scrutiny over clinical-stage pipeline dependency; no recent earnings beat reported in public memory as of late 2026.
• Small-cap biopharma names have seen capital rotation away from unprofitable names amid higher-rate environment.
• Potential catalyst: any late-stage trial update or partnership announcement could re-rate the stock sharply.
• Context: The embedded data shows a steady multi-week decline from $13.58 (Sep 21) to $10.34 (Oct 21), consistent with weak sector sentiment for non-revenue biopharma.

This news context is separated from the data-driven analysis below, which uses only the embedded JSON.

Fundamental Analysis

Based strictly on the FUNDAMENTALS data provided:

• Market Cap: $571,203,500.00 with Shares Outstanding: 57,700,000.00
• Trailing P/E: null; Forward P/E: null; PEG Ratio: null — no valuation multiple available
• Trailing EPS: null; Forward EPS: null — no earnings data reported
• Revenue, margins, ROE, Debt/Equity, FCF: all null — not disclosed in data
• Dividend Yield: 0.00%; no dividend
• 52-Week High: $19.69; 52-Week Low: $10.07 — price near 52-week low
• Institutional Ownership: 30.50%
• Average Volume: 2,666,000.00; Historical Volatility: 51.98%
• Analyst Target Mean: null; Number of Opinions: null — no consensus

Fundamentals show a micro-cap with no reported revenue or earnings, trading near its 52-week low. This aligns with the weak technical picture (price below all SMAs) and suggests fundamental uncertainty diverges from any bullish hope — the data shows no profit engine to support reversal.

Current Market Position

Current price per indicators: $10.34 (as of 2026-10-21 close). Minute bars show 2026-10-22 15:05 close at $10.26, with tight range $10.25–$10.26 in final bars.

Recent daily action: Oct 21 close $10.34, down from Oct 20 $10.36; 30-day range high $13.64, low $10.31. Price is at the very bottom of 30-day range.

Intraday momentum: Opening 2026-10-21 09:30 at $10.38, drift to $10.26 by 2026-10-22 15:05; volume spikes (e.g., 165,935 at 15:05) with flat prices signal indecision.

Technical Analysis

SMA alignment: Price ($10.34) < SMA5 ($10.63) < SMA20 ($11.35) < SMA50 ($12.87) — full bearish stack, no crossovers bullish. RSI 33.46 indicates weak momentum but not yet oversold (<30). MACD negative with histogram -0.13 confirms bearish pressure. Bollinger: price near lower band ($10.04), below middle ($11.35) — expansion to downside. 30-day range: price at $10.34 vs low $10.31, essentially at floor.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-22 15:32) shows Balanced sentiment:

Call Dollar Volume: $515,900.00 (46.3%) Put Dollar Volume: $598,800.00 (53.7%) Total: $1,114,700.00

Call contracts 4,064 vs put 1,814; only 7 of 232 options analyzed (3.0% filter). Pure directional conviction is balanced — no strong bias. This diverges from deeply bearish technicals (price at 30-day low, RSI weak), suggesting options players are not adding downside aggression despite price weakness.

Key Price Levels (Observational Only)